US20160303077A1 - Novel compositions - Google Patents

Novel compositions Download PDF

Info

Publication number
US20160303077A1
US20160303077A1 US15/102,949 US201415102949A US2016303077A1 US 20160303077 A1 US20160303077 A1 US 20160303077A1 US 201415102949 A US201415102949 A US 201415102949A US 2016303077 A1 US2016303077 A1 US 2016303077A1
Authority
US
United States
Prior art keywords
composition
azabicyclo
naphthalen
hexane
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/102,949
Other languages
English (en)
Inventor
Anthony McKinney
Brian McMillan
Matthew Greene
Walter Piskorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka America Pharmaceutical Inc
Original Assignee
Neurovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovance Inc filed Critical Neurovance Inc
Priority to US15/102,949 priority Critical patent/US20160303077A1/en
Assigned to NEUROVANCE, INC. reassignment NEUROVANCE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCKINNEY, ANTHONY, PISKORSKI, WALTER
Assigned to CORERX, INC. reassignment CORERX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCMILLAN, BRIAN, GREENE, MATTHEW
Assigned to NEUROVANCE, INC. reassignment NEUROVANCE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CORERX, INC.
Publication of US20160303077A1 publication Critical patent/US20160303077A1/en
Assigned to OTSUKA AMERICA PHARMACEUTICAL, INC. reassignment OTSUKA AMERICA PHARMACEUTICAL, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NEUROVANCE, INC.
Assigned to OTSUKA AMERICA PHARMACEUTICAL, INC. reassignment OTSUKA AMERICA PHARMACEUTICAL, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NEUROVANCE, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
  • composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
  • substantially free of the corresponding ( ⁇ ) enantiomer means more of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane than the corresponding ( ⁇ ) enantiomer, i.e., (1S,5R)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane.
  • “substantially free of the corresponding ( ⁇ ) enantiomer” means containing no more than 20% w/w (weight/weight) of the corresponding ( ⁇ ) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 10% w/w of the corresponding ( ⁇ ) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 5% w/w of the corresponding ( ⁇ ) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 2% w/w of the corresponding ( ⁇ ) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 1% w/w of the corresponding ( ⁇ ) enantiomer, in free or pharmaceutically acceptable salt form.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane embraces the compound in any form, for example, free or pharmaceutically acceptable salt form, e.g., as a pharmaceutically acceptable acid addition salt.
  • Pharmaceutically acceptable salts are known in the art and include salts that are physiologically acceptable at the dosage amount and form to be administered, for example, hydrochloride salts.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is also to be understood as embracing the compound in crystalline and amorphous form including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof.
  • Crystal form and “polymorph” may be used interchangeably herein, and are meant to include all crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), and conformational polymorphs, as well as mixtures thereof, unless a particular crystalline form is referred to.
  • Crystalline and amorphous forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may be used in any combination or in forms that are substantially free of one or more of the other crystalline forms or free of the amorphous form.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may in some cases also exist in prodrug form.
  • Prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo.
  • “concurrently” means the compounds are administered simultaneously or within the same composition. In some embodiments, the compounds are administered simultaneously. In some embodiments, the compounds are administered within the same composition.
  • the nominal viscosity of polymers e.g., hydroxypropyl methylcellulose may be measured, for example, at a 2% concentration in water at 20° C. according to the U.S. Pharmacopeia and by other techniques known to those skilled in the art.
  • Particle size measurements may be made, for example, by laser diffraction and by other techniques known to those skilled in the art.
  • compositions disclosed herein comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, including by sustained release, although various other known delivery routes, devices and methods can likewise be employed.
  • a sustained release pharmaceutical composition e.g., an oral sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, which provides therapeutically effective levels of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane over a sustained delivery period of approximately 6 hours or longer, e.g., 8 hours or longer, e.g., 12 hours or longer, e.g., 18 hours or longer, e.g., 24 hours or longer.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that from about 0% to 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 0 to 2 hours, from 20% to 50% of the active compound is released and delivered within about 2 to 12 hours, from 50% to 85% of the active compound is released and delivered within about 3 to 20 hours, and greater than 75% of the active compound is released and delivered within about 5 to 18 hours.
  • a pharmaceutical composition as disclosed herein and
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 4 or less hours after administration, e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 40-60% is released and delivered within 4 hours or less after administration.
  • a pharmaceutical composition
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 50% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 8 hours or less after administration, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is
  • At least 20% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 30-60%, e.g., about 40-60%, e.g., about 50-60%, e.g., about 50%, e.g., about 60%, is released and dissolved within 4 hours or less (e.g., within about 2-4 hours, e.g., about within 3-4 hours, e.g., about 4 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and at 37° C. ⁇ 0.5.
  • a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and at 37
  • At least 50% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is released and dissolved within 8 hours or less (e.g., within about 6-8 hours, e.g., within about 7-8 hours, e.g., about 8 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and 37° C. ⁇ 0.5.
  • the C max of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 80%, e.g., less than about 75%, e.g., less than about 60%, e.g., less than about 50%, e.g., less than about 40%, e.g., less than about 30% of the C max obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
  • the C max of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-80%, e.g., is about 30-80%, e.g., is about 20-70% e.g., is about 30-70%, e.g., is about 30-60%, e.g., is about 30-50%, e.g., is about 30-40%, of the C max obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
  • (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 50%, e.g., less than about 40%, e.g., less than about 30%, of the C max obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
  • the C max of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-50%, e.g., is about 30-50%, e.g., is about 30-40%, of the C max obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
  • the pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, e.g., a sustained release pharmaceutical composition, comprises a lubricant, e.g., magnesium stearate, a carrier, e.g., lactose monohydrate, or a combination thereof.
  • a lubricant e.g., magnesium stearate
  • a carrier e.g., lactose monohydrate, or a combination thereof.
  • composition 1 e.g., a sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
  • Composition 1 as follows:
  • Sustained release pharmaceutical compositions comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride may be made utilizing a direct blend process, with screening of the excipients and (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride through a Quadro 197S Co-Mil, and blending in a V-shell blender prior to compression on a rotary tablet press.
  • HPLC conditions for dissolution and dissolution conditions for Examples 3-9 are set forth in Tables 1 and 2.
  • Batch has an approximate 50% dissolution release at 4 hours and approximate 80% release at 8 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US15/102,949 2013-12-09 2014-12-09 Novel compositions Abandoned US20160303077A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/102,949 US20160303077A1 (en) 2013-12-09 2014-12-09 Novel compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913886P 2013-12-09 2013-12-09
PCT/US2014/069416 WO2015102826A1 (en) 2013-12-09 2014-12-09 Novel compositions
US15/102,949 US20160303077A1 (en) 2013-12-09 2014-12-09 Novel compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/069416 A-371-Of-International WO2015102826A1 (en) 2013-12-09 2014-12-09 Novel compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US202117443763A Continuation 2013-12-09 2021-07-27

Publications (1)

Publication Number Publication Date
US20160303077A1 true US20160303077A1 (en) 2016-10-20

Family

ID=53371779

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/102,949 Abandoned US20160303077A1 (en) 2013-12-09 2014-12-09 Novel compositions
US15/102,871 Active US9839627B2 (en) 2013-12-09 2014-12-09 Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
US17/691,911 Abandoned US20220347157A1 (en) 2013-12-09 2022-03-10 Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/102,871 Active US9839627B2 (en) 2013-12-09 2014-12-09 Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
US17/691,911 Abandoned US20220347157A1 (en) 2013-12-09 2022-03-10 Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane

Country Status (8)

Country Link
US (3) US20160303077A1 (enrdf_load_stackoverflow)
EP (1) EP3080080A4 (enrdf_load_stackoverflow)
JP (1) JP2017502948A (enrdf_load_stackoverflow)
KR (1) KR20160101012A (enrdf_load_stackoverflow)
CN (1) CN106029637A (enrdf_load_stackoverflow)
AU (1) AU2014374259A1 (enrdf_load_stackoverflow)
CA (1) CA2936108A1 (enrdf_load_stackoverflow)
WO (2) WO2015089111A1 (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737506B2 (en) 2005-07-27 2017-08-22 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US9839627B2 (en) 2013-12-09 2017-12-12 Neurovance, Inc. Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3597189T (pt) 2015-06-17 2022-07-05 Otsuka America Pharmaceutical Inc Compostos cristalinos
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
CN118439973A (zh) 2018-04-26 2024-08-06 株式会社Api 芳香族腈化合物的制造方法
KR20220088777A (ko) 2019-10-29 2022-06-28 가부시키가이샤 에이피아이 코포레이션 고순도 2-나프틸아세토니트릴 및 이의 제조 방법
JP2024506595A (ja) 2021-02-23 2024-02-14 大塚製薬株式会社 センタナファジン製剤ならびにその製造および使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082940A1 (en) * 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096810A2 (en) 2005-03-08 2006-09-14 Dov Pharmaceutical, Inc. Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20080058535A1 (en) 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
KR20140053822A (ko) * 2010-12-03 2014-05-08 유티믹스 바이오사이언스 인코포레이티드 (+)-1-(3,4-디클로로페닐)-3-아자비시클로[3.1.0]헥산의 제조방법 및 모노아민 신경전달물질에 의해 영향을 받는 병태를 치료하기 위한 용도
JP2014515008A (ja) 2011-03-03 2014-06-26 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
ES2779032T3 (es) * 2011-07-30 2020-08-13 Otsuka America Pharmaceutical Inc Uso de (1R,5S)-(+)-1-(naftalen-2-il)-3-azabiciclo{3.1.0}hexano en el tratamiento de estados afectados por neurotransmisores de monoamina
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20160303077A1 (en) 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
PT3597189T (pt) * 2015-06-17 2022-07-05 Otsuka America Pharmaceutical Inc Compostos cristalinos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082940A1 (en) * 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RetaLac®, a new Excipient for Direct Compression of Sustained Release Formulations" (PharmTech.com (July 9, 2010)) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737506B2 (en) 2005-07-27 2017-08-22 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US10039746B2 (en) 2005-07-27 2018-08-07 Otsuka America Pharmaceutical, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US9839627B2 (en) 2013-12-09 2017-12-12 Neurovance, Inc. Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder

Also Published As

Publication number Publication date
CN106029637A (zh) 2016-10-12
US9839627B2 (en) 2017-12-12
KR20160101012A (ko) 2016-08-24
CA2936108A1 (en) 2015-07-09
JP2017502948A (ja) 2017-01-26
US20220347157A1 (en) 2022-11-03
WO2015102826A1 (en) 2015-07-09
US20160303076A1 (en) 2016-10-20
WO2015089111A1 (en) 2015-06-18
EP3080080A1 (en) 2016-10-19
AU2014374259A1 (en) 2016-07-21
EP3080080A4 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
US20220347157A1 (en) Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane
AU2021229240B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
US20070265276A1 (en) Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
US20060264511A1 (en) Method for the treatment of drug-induced sexual dysfunction
US20190030033A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
HUP0402104A2 (hu) 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenolt tartalmazó, késleltetett hatóanyag-leadású gyógyszer
KR101307334B1 (ko) 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
US11273156B2 (en) Stable cariprazine formulations for oral use
US20160015643A1 (en) Formulations of organic compounds
US20230157947A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
US20080193527A1 (en) Pharmaceutical compositions containing quetiapine fumarate
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US20120277257A1 (en) Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms
US20180147148A1 (en) Pharmaceutical composition of teriflunomide
KR20090013736A (ko) 메트포르민 산 부가염을 포함하는 서방성 제제
US20250195440A1 (en) Pharmaceutical formulation comprising glucokinase activator and use thereof
US20120329831A1 (en) Pharmaceutical composition of donepezil
US20250134820A1 (en) Pharmaceutical compositions
WO2023080854A1 (en) Lurasidone hydrochloride compositions
CN107157945B (zh) 一种新型阿片δ受体激动剂盐酸盐的片剂及其制备方法
US20180000811A1 (en) Stable pharmaceutical compositions comprising antibacterial agent
US20220175774A1 (en) Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor
CN119074728A (zh) 用于高血压治疗的多重释放组合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROVANCE, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCKINNEY, ANTHONY;PISKORSKI, WALTER;SIGNING DATES FROM 20160608 TO 20160609;REEL/FRAME:039869/0278

Owner name: CORERX, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCMILLAN, BRIAN;GREENE, MATTHEW;SIGNING DATES FROM 20160610 TO 20160713;REEL/FRAME:039869/0452

AS Assignment

Owner name: NEUROVANCE, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORERX, INC.;REEL/FRAME:039872/0862

Effective date: 20160714

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: OTSUKA AMERICA PHARMACEUTICAL, INC., MARYLAND

Free format text: MERGER;ASSIGNOR:NEUROVANCE, INC.;REEL/FRAME:047693/0879

Effective date: 20171130

Owner name: OTSUKA AMERICA PHARMACEUTICAL, INC., MARYLAND

Free format text: MERGER;ASSIGNOR:NEUROVANCE, INC.;REEL/FRAME:047697/0210

Effective date: 20171130

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION